search
Back to results

Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension

Primary Purpose

Hypotension, Orthostatic, Hypertension, Autonomic Nervous System Diseases

Status
Terminated
Phase
Early Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Yohimbine
Melatonin
Sponsored by
Lawson Health Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypotension, Orthostatic focused on measuring Melatonin, Yohimbine, Anti-hypertensive agents

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Control population: Healthy males or females between the ages of 18-80.
  • Patient population: Males or females who have been previously diagnosed with Neurogenic Orthostatic Hypotension.

Exclusion Criteria:

Patient population:

  1. Medical therapies or medications which could interfere with testing of autonomic function.
  2. Clinically significant heart disease.
  3. Presence of unrelated nerve damage in the peripheral nervous system.
  4. Pregnant or breast feeding females.
  5. The presence of failure of other organ systems or systemic illness that can affect autonomic function or your ability to cooperate. These include dementia, heart failure, kidney or liver disease, severe anemia, alcoholism, any new and abnormal cell growth identified as malignant, hypothyroidism, surgical procedures where the nerves of the sympathetic nervous system have been cut, or cerebrovascular disease.

Exclusion criteria for monitoring the effects of melatonin

1. All the above PLUS No lying/night time hypertension as determined by 24-hour blood pressure monitoring

Exclusion criteria for healthy controls:

  1. Presence of ANY autonomic dysfunction
  2. Medical therapies or medications which could interfere with testing of autonomic function.
  3. Clinically significant heart disease.
  4. Presence of ANY nerve damage in the peripheral nervous system.
  5. Pregnant or breast feeding females.
  6. The presence of failure of other organ systems or systemic illness that can affect autonomic function or your ability to cooperate. These include dementia, heart failure, kidney or liver disease, severe anemia, alcoholism, any new and abnormal cell growth identified as malignant, hypothyroidism, surgical procedures where the nerves of the sympathetic nervous system have been cut, or cerebrovascular disease.

Sites / Locations

  • University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Effects of Yohimbine

Effects of melatonin on blood pressure

Arm Description

Investigation into the integrity of post-ganglionic sympathetic nerves in patients with idiopathic neurogenic orthostatic hypotension

Investigation into the effects of melatonin at two separate dosages (2 and 5mg) on nocturnal blood pressure in NOH patients with intact versus denervated post-ganglionic sympathetic nerves

Outcomes

Primary Outcome Measures

Investigation into the integrity of post-ganglionic sympathetic nerves in idiopathic NOH
Markers of post-ganglionic sympathetic function will be examined (i.e. sympathetic blood markers, heart rate, blood pressure, sympathetic nerve activity, etc.)
Effects of melatonin on supine hypertension in persons with neurogenic orthostatic hypotension
Supine systolic blood pressure
Effects of melatonin on supine hypertension in patients with neurogenic orthostatic hypotension
Change in postural (supine-standing) systolic blood pressure

Secondary Outcome Measures

Serum markers of sympathetic activation
Carotid artery diameter
Sympathetic nerve activation using microneurography
Orthostatic symptoms based on standard autonomic symptom questionnaires
Sleep quality assessment using Epworth Sleepiness Scale
Urine and Saliva melatonin levels

Full Information

First Posted
November 7, 2016
Last Updated
June 10, 2019
Sponsor
Lawson Health Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT02963181
Brief Title
Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension
Official Title
Identifying the Pathophysiology of Neurogenic Orthostatic Hypotension and the Effects of Melatonin on Reducing Supine Hypertension in Peripherally Intact Versus Denervated Post-ganglionic Sympathetic Nerves
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Terminated
Why Stopped
PI leaving
Study Start Date
March 1, 2018 (Actual)
Primary Completion Date
May 28, 2019 (Actual)
Study Completion Date
May 28, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lawson Health Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Neurogenic Orthostatic Hypotension (NOH) is clinically defined as a consistent drop in systolic blood pressure (SBP) ≥30mmHg upon standing from a seated or lying position. However, 50% of NOH patients also have associated supine hypertension. It has been proposed that supine hypertension is the result of intact post-ganglionic sympathetic nerves and therefore due to residual sympathetic tone. Furthermore, research investigating the effects of melatonin shows blood pressure implication of this naturally secreted hormone. Specifically, melatonin has been investigated as a non-traditional anti-hypertensive agent for patients with essential and nocturnal hypertension. Central and peripheral mechanisms have been proposed to help explain how melatonin reduces blood pressures. Therefore, we aim to identify NOH patients as having either intact or denervated post-ganglionic sympathetic nerves, monitor the correlation to supine hypertension and subsequently investigate the effects of melatonin on blood pressure in these patients.
Detailed Description
Neurogenic orthostatic hypotension (NOH) is a debilitating condition associated with reduced quality of life, impaired function and is also an independent predictor of mortality(Bendini et al., 2007; Cordeiro et al., 2009; Rose et al., 2006). NOH is clinically defined as a sustained reduction in systolic blood pressure (SBP) ≥30mmHg within 3 minutes of standing or head-up tilt to at least 60 degrees on a tilt table(Freeman et al., 2011). Specifically, neurogenic OH can be differentiated from other causes of orthostatic hypotension, such as hypotension due to endocrine issues, generalized low blood pressure, low blood volume, etc., in that NOH is associated with autonomic dysfunction. Specifically, dysfunction of the reflexive regulation mediated by the sympathetic nervous system(Goldstein and Sharabi, 2009; Low et al., 2008). Studies have implicated specific dysfunction of the peripheral sympathetic nerves in disorders that have accompanying NOH such as Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF) and Parkinson Disease (PD+NOH)(Imrich et al., 2009; Senard et al., 1993; Sharabi et al., 2006). In clinical NOH populations with known diagnoses such as MSA, PAF and PD+NOH, infusions of yohimbine have been used to detect whether post-ganglionic sympathetic nerves are intact or denervated. Yohimbine is an alpha-adrenoceptor antagonist that, in healthy/intact sympathetic nerves, causes an increase in the release of norepinephrine (NE) from sympathetic nerves via increased sympathetic neuronal outflow. NE is a natural neurotransmitter that is released when the sympathetic nervous system is required to increase its activity. In persons with intact post-ganglionic sympathetic nerves an infusion of yohimbine results in an increase in blood pressure, arterial NE levels, and heart rate levels, with a decrease in forearm blood flow indicative of vasoconstriction. In contrast, patients with sympathetic denervation these responses are attenuated(Senard et al., 1993; Shannon et al., 2000; Sharabi et al., 2006). However, in these studies, the clinical population consisted of MSA, PAF and PD+NOH. Little research has been done in NOH populations without an underlying diagnosis, and in fact, 1/3 of patients with NOH have no identifiable underlying cause (Robertson and Robertson, 1994). Furthermore, it has been hypothesized that supine hypertension in this select patient population is due to residual sympathetic tone in patients with intact post-ganglionic sympathetic nerves. Approximately 50% of NOH patients have associated supine hypertension(Shannon et al., 2000), which if left untreated, comes with its very own unique set of cardiovascular complications, such as significantly higher left-ventricular mass indices, specific end organ damage(Vagaonescu et al., 2000), heart attack and stroke. Therefore, clinicians are left with the challenging dilemma of finding a near impossible balance between the risks associated with supine hypertension versus the risks of sudden hypotension upon standing and the associated consequences of falls, fractures and head injuries resulting in more immediately morbid events. Medications such as nitrates and other antihypertensives can be prescribed, however their use is strongly cautioned as it is quite frequent that NOH patients are often older and have nocturia, and as a result are up frequently throughout the night. Other options such as raising the head of the bed 4 inches from the ground in order to reduced renal hyper-perfusion pose as an additional conservative measure, however, this does not act as a treatment for the supine hypertension. In contrast, melatonin is a natural hormone secreted by the pineal gland in response to low light and is involved in maintaining proper circadian rhythms and sleep patterns. However, more recently, there has been a growing source of literature supporting melatonin as having an important role in blood pressure control: i) In rats, following pinealectomy, there is evidence of vasoconstriction (Cunnane et al., 1980) and hypertension (Zanoboni et al., 1978; Zanoboni and Zanoboni-Muciaccia, 1967). ii) Experimental hypertension elicited via pinealectomy can be reversed through exogenous administration of melatonin(Holmes and Sugden, 1976). iii) Continuous light exposure, results in a melatonin deficiency, peripheral vasoconstriction and hypertension(Briaud et al., 2004; Brown et al., 1991). Therefore, melatonin is now being looked at as a non-traditional anti-hypertensive medication in patients with essential and nocturnal hypertension. In a study of 34 patients with nocturnal hypertension, administration of melatonin proved to have a slight, yet significant, reduction in nighttime blood pressure measurements(Grossman et al., 2006). In these studies, melatonin was taken for 3 or 4 weeks via an oral prescription 1 hour before bed. The dose was formulated as a controlled- or slow-release throughout the night. In these studies, there was an average systolic BP drop of 6.5mmHg and 4mmHg diastolic in supine/nighttime blood pressures. While this reduction may not seem significant, clinical it is. In a study of 2156 hypertensive patients, following a median follow-up period of 5.6 years it was found that the cardiovascular risk adjustment per 5mmHg reduction of nocturnal blood pressure in patients aged 55 years and above, was 0.92 (95%CI0.88-0.96) and per 5mmHg reduction in nocturnal diastolic blood pressure was 0.82 (95%CI0.77-0.88). The decrease in mean asleep BP during follow-up was most significantly associated with event-free survival (Hermida et al., 2010). In women, a mean decrease of 6mmHg in diastolic pressure significantly reduced overall mortality from vascular disease by 21%, fatal and nonfatal stroke by 42%, and fatal and nonfatal coronary heart disease by 14% (Rich-Ewards et al., 1995). Currently, the posed mechanisms of melatonin to reduced blood pressure consist of both central and peripheral mechanisms (Capsoni et al., 1994; Pogan et al., 2002; Ray, 2003; Satake et al., 1991; Stankov et al., 1993; Weekley, 1993). Therefore, the objectives of the current study are: 1. Identify NOH patients as having either peripherally intact vs denervated post-ganglionic sympathetic innervation to help identify a group of patients potentially more susceptible to supine hypertension. 2. Administer melatonin and monitor its effects on supine/nocturnal blood pressures in patients with supine hypertension, and 3. Investigate the proposed mechanisms of melatonin by comparing its effects in patients with peripherally intact vs denervated sympathetic nerves.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypotension, Orthostatic, Hypertension, Autonomic Nervous System Diseases
Keywords
Melatonin, Yohimbine, Anti-hypertensive agents

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Effects of Yohimbine
Arm Type
Experimental
Arm Description
Investigation into the integrity of post-ganglionic sympathetic nerves in patients with idiopathic neurogenic orthostatic hypotension
Arm Title
Effects of melatonin on blood pressure
Arm Type
Experimental
Arm Description
Investigation into the effects of melatonin at two separate dosages (2 and 5mg) on nocturnal blood pressure in NOH patients with intact versus denervated post-ganglionic sympathetic nerves
Intervention Type
Drug
Intervention Name(s)
Yohimbine
Other Intervention Name(s)
DIN:01901885
Intervention Description
Oral Yohimbine will be used to identify the integrity of post-ganglionic sympathetic nerves in patients with NOH
Intervention Type
Drug
Intervention Name(s)
Melatonin
Other Intervention Name(s)
melatonin timed release; 2 or 5 mg
Intervention Description
Monitor the effects of melatonin on supine hypertension in NOH patients with intact and denervated post-ganglionic nerves. Identify the mechanistic pathway of melatonin in blood pressure regulation
Primary Outcome Measure Information:
Title
Investigation into the integrity of post-ganglionic sympathetic nerves in idiopathic NOH
Description
Markers of post-ganglionic sympathetic function will be examined (i.e. sympathetic blood markers, heart rate, blood pressure, sympathetic nerve activity, etc.)
Time Frame
Sympathetic markers will be assessed during and immediately following the test. A comparison between healthy participants and NOH patients will be ongoing throughout recruitment and upon completion of study recruitment
Title
Effects of melatonin on supine hypertension in persons with neurogenic orthostatic hypotension
Description
Supine systolic blood pressure
Time Frame
4 weeks
Title
Effects of melatonin on supine hypertension in patients with neurogenic orthostatic hypotension
Description
Change in postural (supine-standing) systolic blood pressure
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Serum markers of sympathetic activation
Time Frame
Before and during stimulation of sympathetic nervous system
Title
Carotid artery diameter
Time Frame
During stimulation of sympathetic nervous system
Title
Sympathetic nerve activation using microneurography
Time Frame
During stimulation of sympathetic nervous system
Title
Orthostatic symptoms based on standard autonomic symptom questionnaires
Time Frame
30 minutes before testing
Title
Sleep quality assessment using Epworth Sleepiness Scale
Time Frame
Assessed at pre- and post- melatonin treatment; week 1 and week 5 of melatonin intervention timeframe
Title
Urine and Saliva melatonin levels
Time Frame
Assessed at pre- and post- melatonin treatment; week 1 and week 5 of melatonin intervention timeframe

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Control population: Healthy males or females between the ages of 18-80. Patient population: Males or females who have been previously diagnosed with Neurogenic Orthostatic Hypotension. Exclusion Criteria: Patient population: Medical therapies or medications which could interfere with testing of autonomic function. Clinically significant heart disease. Presence of unrelated nerve damage in the peripheral nervous system. Pregnant or breast feeding females. The presence of failure of other organ systems or systemic illness that can affect autonomic function or your ability to cooperate. These include dementia, heart failure, kidney or liver disease, severe anemia, alcoholism, any new and abnormal cell growth identified as malignant, hypothyroidism, surgical procedures where the nerves of the sympathetic nervous system have been cut, or cerebrovascular disease. Exclusion criteria for monitoring the effects of melatonin 1. All the above PLUS No lying/night time hypertension as determined by 24-hour blood pressure monitoring Exclusion criteria for healthy controls: Presence of ANY autonomic dysfunction Medical therapies or medications which could interfere with testing of autonomic function. Clinically significant heart disease. Presence of ANY nerve damage in the peripheral nervous system. Pregnant or breast feeding females. The presence of failure of other organ systems or systemic illness that can affect autonomic function or your ability to cooperate. These include dementia, heart failure, kidney or liver disease, severe anemia, alcoholism, any new and abnormal cell growth identified as malignant, hypothyroidism, surgical procedures where the nerves of the sympathetic nervous system have been cut, or cerebrovascular disease.
Facility Information:
Facility Name
University Hospital
City
London
State/Province
Ontario
ZIP/Postal Code
N6A5A5
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
17317436
Citation
Bendini C, Angelini A, Salsi F, Finelli ME, Martini E, Neviani F, Mussi C, Neri M. Relation of neurocardiovascular instability to cognitive, emotional and functional domains. Arch Gerontol Geriatr. 2007;44 Suppl 1:69-74. doi: 10.1016/j.archger.2007.01.010.
Results Reference
background
PubMed Identifier
16423108
Citation
Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Baker G, Klassen TP, Vohra S. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med. 2005 Dec;20(12):1151-8. doi: 10.1111/j.1525-1497.2005.0243.x.
Results Reference
background
PubMed Identifier
16364834
Citation
Cagnacci A, Cannoletta M, Renzi A, Baldassari F, Arangino S, Volpe A. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am J Hypertens. 2005 Dec;18(12 Pt 1):1614-8. doi: 10.1016/j.amjhyper.2005.05.008.
Results Reference
background
PubMed Identifier
8013371
Citation
Capsoni S, Viswanathan M, De Oliveira AM, Saavedra JM. Characterization of melatonin receptors and signal transduction system in rat arteries forming the circle of Willis. Endocrinology. 1994 Jul;135(1):373-8. doi: 10.1210/endo.135.1.8013371.
Results Reference
background
PubMed Identifier
19942985
Citation
Cordeiro RC, Jardim JR, Perracini MR, Ramos LR. Factors associated with functional balance and mobility among elderly diabetic outpatients. Arq Bras Endocrinol Metabol. 2009 Oct;53(7):834-43. doi: 10.1590/s0004-27302009000700007.
Results Reference
background
PubMed Identifier
21431947
Citation
Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, Cheshire WP, Chelimsky T, Cortelli P, Gibbons CH, Goldstein DS, Hainsworth R, Hilz MJ, Jacob G, Kaufmann H, Jordan J, Lipsitz LA, Levine BD, Low PA, Mathias C, Raj SR, Robertson D, Sandroni P, Schatz I, Schondorff R, Stewart JM, van Dijk JG. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011 Apr;21(2):69-72. doi: 10.1007/s10286-011-0119-5. No abstract available.
Results Reference
background
PubMed Identifier
19124673
Citation
Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009 Jan 6;119(1):139-46. doi: 10.1161/CIRCULATIONAHA.108.805887. No abstract available.
Results Reference
background
PubMed Identifier
17000226
Citation
Grossman E, Laudon M, Yalcin R, Zengil H, Peleg E, Sharabi Y, Kamari Y, Shen-Orr Z, Zisapel N. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med. 2006 Oct;119(10):898-902. doi: 10.1016/j.amjmed.2006.02.002.
Results Reference
background
PubMed Identifier
20854139
Citation
Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010 Sep;27(8):1629-51. doi: 10.3109/07420528.2010.510230.
Results Reference
background
PubMed Identifier
18514012
Citation
Imrich R, Eldadah BA, Bentho O, Pechnik S, Sharabi Y, Holmes C, Grossman E, Goldstein DS. Functional effects of cardiac sympathetic denervation in neurogenic orthostatic hypotension. Parkinsonism Relat Disord. 2009 Feb;15(2):122-7. doi: 10.1016/j.parkreldis.2008.04.002. Epub 2008 May 29.
Results Reference
background
PubMed Identifier
12121484
Citation
Pogan L, Bissonnette P, Parent L, Sauve R. The effects of melatonin on Ca(2+) homeostasis in endothelial cells. J Pineal Res. 2002 Aug;33(1):37-47. doi: 10.1034/j.1600-079x.2002.01890.x.
Results Reference
background
PubMed Identifier
12869610
Citation
Ray CA. Melatonin attenuates the sympathetic nerve responses to orthostatic stress in humans. J Physiol. 2003 Sep 15;551(Pt 3):1043-8. doi: 10.1113/jphysiol.2003.043182. Epub 2003 Jul 17.
Results Reference
background
PubMed Identifier
7760894
Citation
Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med. 1995 Jun 29;332(26):1758-66. doi: 10.1056/NEJM199506293322607. No abstract available.
Results Reference
background
PubMed Identifier
8031210
Citation
Robertson D, Robertson RM. Causes of chronic orthostatic hypotension. Arch Intern Med. 1994 Jul 25;154(14):1620-4.
Results Reference
background
PubMed Identifier
16894039
Citation
Rose KM, Eigenbrodt ML, Biga RL, Couper DJ, Light KC, Sharrett AR, Heiss G. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) Study. Circulation. 2006 Aug 15;114(7):630-6. doi: 10.1161/CIRCULATIONAHA.105.598722. Epub 2006 Aug 7.
Results Reference
background
PubMed Identifier
1667303
Citation
Satake N, Oe H, Shibata S. Vasorelaxing action of melatonin in rat isolated aorta; possible endothelium dependent relaxation. Gen Pharmacol. 1991;22(6):1127-33. doi: 10.1016/0306-3623(91)90589-x.
Results Reference
background
PubMed Identifier
14732734
Citation
Scheer FA, Van Montfrans GA, van Someren EJ, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension. 2004 Feb;43(2):192-7. doi: 10.1161/01.HYP.0000113293.15186.3b. Epub 2004 Jan 19.
Results Reference
background
PubMed Identifier
8422659
Citation
Senard JM, Rascol O, Durrieu G, Tran MA, Berlan M, Rascol A, Montastruc JL. Effects of yohimbine on plasma catecholamine levels in orthostatic hypotension related to Parkinson disease or multiple system atrophy. Clin Neuropharmacol. 1993 Feb;16(1):70-6. doi: 10.1097/00002826-199302000-00008.
Results Reference
background
PubMed Identifier
10851208
Citation
Shannon JR, Jordan J, Diedrich A, Pohar B, Black BK, Robertson D, Biaggioni I. Sympathetically mediated hypertension in autonomic failure. Circulation. 2000 Jun 13;101(23):2710-5. doi: 10.1161/01.cir.101.23.2710.
Results Reference
background
PubMed Identifier
16772807
Citation
Sharabi Y, Eldadah B, Li ST, Dendi R, Pechnik S, Holmes C, Goldstein DS. Neuropharmacologic distinction of neurogenic orthostatic hypotension syndromes. Clin Neuropharmacol. 2006 May-Jun;29(3):97-105. doi: 10.1097/01.WNF.0000220822.80640.0D.
Results Reference
background
PubMed Identifier
8383820
Citation
Stankov B, Capsoni S, Lucini V, Fauteck J, Gatti S, Gridelli B, Biella G, Cozzi B, Fraschini F. Autoradiographic localization of putative melatonin receptors in the brains of two Old World primates: Cercopithecus aethiops and Papio ursinus. Neuroscience. 1993 Jan;52(2):459-68. doi: 10.1016/0306-4522(93)90172-c.
Results Reference
background
PubMed Identifier
10703810
Citation
Vagaonescu TD, Saadia D, Tuhrim S, Phillips RA, Kaufmann H. Hypertensive cardiovascular damage in patients with primary autonomic failure. Lancet. 2000 Feb 26;355(9205):725-6. doi: 10.1016/S0140-6736(99)05320-9.
Results Reference
background
PubMed Identifier
8358182
Citation
Weekley LB. Effects of melatonin on isolated pulmonary artery and vein: role of the vascular endothelium. Pulm Pharmacol. 1993 Jun;6(2):149-54. doi: 10.1006/pulp.1993.1019.
Results Reference
background
PubMed Identifier
7378930
Citation
Cunnane SC, Manku MS, Oka M, Horrobin DF. Enhanced vascular reactivity to various vasoconstrictor agents following pinealectomy in the rat: role of melatonin. Can J Physiol Pharmacol. 1980 Mar;58(3):287-93. doi: 10.1139/y80-049.
Results Reference
background
PubMed Identifier
755848
Citation
Zanoboni A, Forni A, Zanoboni-Muciaccia W, Zanussi C. Effect of pinealectomy on arterial blood pressure and food and water intake in the rat. J Endocrinol Invest. 1978 Apr;1(2):125-30. doi: 10.1007/BF03350359.
Results Reference
background
PubMed Identifier
6060280
Citation
Zanoboni A, Zanoboni-Muciaccia W. Experimental hypertension in pinealectomized rats. Life Sci. 1967 Nov 1;6(21):2327-31. doi: 10.1016/0024-3205(67)90043-4. No abstract available.
Results Reference
background
PubMed Identifier
1260192
Citation
Holmes SW, Sugden D. Proceedings: The effect of melatonin on pinealectomy-induced hypertension in the rat. Br J Pharmacol. 1976 Mar;56(3):360P-361P. No abstract available.
Results Reference
background
PubMed Identifier
1880710
Citation
Brown GM, Bar-Or A, Grossi D, Kashur S, Johannson E, Yie SM. Urinary 6-sulphatoxymelatonin, an index of pineal function in the rat. J Pineal Res. 1991 Apr;10(3):141-7. doi: 10.1111/j.1600-079x.1991.tb00831.x.
Results Reference
background
PubMed Identifier
15309246
Citation
Briaud SA, Zhang BL, Sannajust F. Continuous light exposure and sympathectomy suppress circadian rhythm of blood pressure in rats. J Cardiovasc Pharmacol Ther. 2004 Jun;9(2):97-105. doi: 10.1177/107424840400900205.
Results Reference
background

Learn more about this trial

Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension

We'll reach out to this number within 24 hrs